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Metabolomic studies of body fluids show that immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) are associated with metabolic disruption. This is likely to reflect the increased bioenergetic and biosynthetic demands of sustained inflammation and changes in nutrient and oxygen availability in damaged tissue. The synovial membrane lining layer is the principal site of inflammation in RA. Here, the resident cells are fibroblast-like synoviocytes (FLS) and synovial tissue macrophages, which are transformed toward overproduction of enzymes that degrade cartilage and bone and cytokines that promote immune cell infiltration. Recent studies have shown metabolic changes in both FLS and macrophages from RA patients, and these may be therapeutically targetable. However, because the origins and subset-specific functions of synoviocytes are poorly understood, and the signaling modules that control metabolic deviation in RA synovial cells are yet to be explored, significant additional research is needed to translate these findings to clinical application. Furthermore, in many inflamed tissues, different cell types can forge metabolic collaborations through solute carriers in their membranes to meet a high demand for energy or biomolecules. Such relationships are likely to exist in the synovium and have not been studied. Finally, it is not yet known whether metabolic change is a consequence of disease or whether primary changes to cellular metabolism might underlie or contribute to the pathogenesis of earlystage disease. In this review article, we collate what is known about metabolism in synovial tissue cells and highlight future directions of research in this area.
Introduction
Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease that principally manifests in the articular joints. Recent research has yielded biologic therapies and small molecules to target signaling pathways and pathogenic components involved in inflammation and immunity, but in spite of these reasonably successful treatments, very few RA patients are able to achieve and remain in a state of drug-free disease remission. Innovative strategies are needed to obtain new insights into mechanisms that underlie disease pathogenesis and to identify potential new treatments.
In fields such as oncology, the concept of undermining or reprogramming metabolism to improve patient outcomes is established, and we and other investigators believe that using similar strategies in immune-mediated inflammatory diseases has great potential (1,2). For 3 decades, researchers have hypothesized an intermediate role for metabolic alterations and local hypoxia in RA pathology (3, 4) . Indeed, RA and related immune-mediated inflammatory diseases are associated with systemically measurable metabolic disruption. This is likely to reflect the increased bioenergetic and biosynthetic demand placed on immune and stromal cells in a persistently activated state. We now have the tools to better understand and translate past observations and to explore our hypothesis that metabolic deviation in synovial cells has a role in early pathogenesis rather than being a consequence of tissue damage.
Qualitative changes to cellular metabolism are indeed essential to support physiologic and pathologic responses seen in the RA synovium, and we describe these changes below. RA-associated characteristics include proliferation, migration, and invasion, which are hallmarks of activated fibroblast-like synoviocyte (FLS) behavior, and also proinflammatory mediator production, which is characteristic of activated synovial tissue macrophages (5-7). The phenotypic transformation of FLS from a quiescent cell to an aggressive, metabolically active cell, the activation of synovial tissue macrophages, and the increasingly hypoxic and nutrient-deprived microenvironment that develops in the RA joint are characteristics that closely resemble those seen in solid tumors.
Immunometabolism research has recently expanded after lessons were gleaned from the more advanced cancer literature, and this has led to the identification of potential new drug targets for immune-mediated pathologies (1, 8) . Limitation of metabolic substrate availability, modulation of signaling pathways that control metabolism, and targeting of channels through which metabolic intermediates are shared are exciting new strategies for treatment. Because there is now widespread acceptance that the future of RA treatment may lie in targeting synovial tissue and in particular the stromal cell microenvironment, it is logical to apply new therapies targeting metabolism in the synovium (9, 10) . In this review article, we describe our current knowledge of synovial metabolism and the therapeutic opportunities this field might present. We focus on FLS and synovial tissue macrophages, which together form a destructive frontier (pannus), the aberrant behavior of which is underpinned by pathologic metabolic changes.
A systemic metabolic phenotype in RA Metabolic perturbations have long been associated with RA, and the hallmark "calor" (heat) observed in the rheumatoid joint is widely considered to be a consequence of metabolic activity. Daily whole-body resting energy expenditure is 8% higher in patients with RA than in healthy individuals, which suggests that these metabolic changes are significant and systemic (11) . RA patients have an increased susceptibility to cardiovascular comorbidity and metabolic syndrome during the progression of their disease that is associated with disruption of lipid and glucose metabolism (12) . Furthermore, the catabolic condition "cachexia" occurs in patients with RA, with muscle atrophy and increase in body fat associated with systemically elevated levels of proinflammatory cytokines such as tumor necrosis factor (TNF), interleukin-1b (IL1b), leukocyte inhibitory factor, interferon-c (IFNc), and IL-6 (13) .
Untargeted metabolomic studies of body fluids are helping to characterize the observed systemic symptoms and changes alluded to above. These involve analysis of small molecules (<3 kd) usually using 1-dimensional nuclear magnetic resonance spectroscopy, or mass spectrometry coupled to gas or liquid phase separation techniques, technologies that our group recently compared and evaluated (14) . This approach has highlighted urinary metabolite signatures that can identify the 6 most prevalent immune-mediated inflammatory diseases (15) and a serum metabolite signature that is correlated with the C-reactive protein (CRP) level and links metabolism with underlying inflammatory mechanisms (16) . Serum (17) and synovial fluid (SF) (18, 19) metabolomic profiles have also demonstrated the potential to distinguish RA from psoriatic arthritis and other diseases (14) . Furthermore, our data and that of other investigators show that patient responses to biologic agents including etanercept and rituximab can be predicted from urine, serum, and plasma metabolic profiles, highlighting the power of metabolomics in stratifying patients and directing RA treatment (20) (21) (22) .
Because immune and stromal cells within the inflamed joints are known to produce inflammatory cytokines, it is likely that they are contributing to the global metabolic phenotype in RA. However, information elucidating the metabolic profiles of individual cell types involved in chronicity or resolution of inflammation has been sparse. Such information will be important to link disease-associated metabolites to pathogenic processes and to gain a full understanding of RA pathogenesis.
The rheumatoid synovium
Although RA is a systemic disease, the major manifestations are joint pain and loss of function. The normal diarthrodial joint is lined with a thin soft tissue membrane, the synovium, that comprises a sublining and a thin intimal lining layer and produces and encapsulates a lubricating hyaluronic acid-rich fluid (23) . Resident to the tissue are 2 heterogeneous and inadequately characterized cell types: 1) synovial tissue macrophages, a mixed population of embryonically seeded cells and cells that have differentiated from circulating monocytes (24, 25) and 2) FLS (mesenchyme-derived cells) that, compared with fibroblasts in other anatomic locations, are characterized by the expression of UDP-glucose 6-dehydrogenase, an enzyme that is required for the synthesis of hyaluronic acid and complement decay-accelerating factor (also known as CD55) (26) . Collaborative networks such as the National Institutes of Health Accelerating Medicines Partnership are facilitating the effective digestion of tissue to obtain pure populations of FLS and synovial tissue macrophages. This, combined with a growing profile of soluble and surface markers and revolutions in fate-mapping and singlecell analysis techniques, is improving our ability to study and understand the functions of these important cells (27, 28) .
The hallmark of RA is a macroscopically visible change in the synovial lining layer that becomes inflamed, hyperplastic, and invasive of local cartilage and bone (29) . This is driven by a complex interaction between chronically activated and epigenetically transformed synoviocytes and infiltrating cells of the innate and adaptive immune systems (5, 30) . Both FLS and synovial tissue macrophages contribute to synovial inflammation by producing mediators that recruit and activate immune cells. Importantly, through production of cytokines such as TNF and granulocyte-macrophage colony-stimulating factor, FLS and synovial tissue macrophages also contribute to one another's chronic activation and survival. These cytokines act on FLS and synovial tissue macrophages in a paracrine manner, helping to drive disease chronicity (30) . However, it is the FLS in the intimal lining that form Figure 1 . Similarities between rheumatoid arthritis (RA) synovium and the solid tumor microenvironment. In both tissues, fibroblasts and macrophages reside in close proximity and within an oxygen-and nutrient-deprived, cytokine-rich environment. Here they sustain mitochondrial damage and take on a chronically activated phenotype supported by increased glycolytic metabolism. In RA, the fibroblasts themselves are proliferative, invasive, and migratory; in cancer, fibroblasts support proliferation, invasion, and metastasis of tumor cells. Adaptive immune cell-fibroblast interactions are different in the tumor microenvironment versus the RA microenvironment. Activated Tcells (green) and B cells (blue) are present in the RA synovium but are suppressed in the tumor microenvironment. Little is known about fibroblast or macrophage metabolism in early RA and the metabolic changes that take place during the transition from health to disease. FLS= fibroblast-like synoviocyte; Mh = macrophage; ROS = reactive oxygen species. the aggressive pannus and are the major effectors of tissue damage through production of extracellular matrixdegrading enzymes such as matrix metalloproteinases and cathepsins (30) .
Although the joint exists at an oxygen tension as low as 8% even in health, the microenvironment in RA is characterized by severe hypoxia at oxygen tensions that fall to <1% (31) . Nutrient availability is also low, because immune cells and activated synoviocytes consume available resources at a rate that exceeds their delivery. Synovial angiogenesis, which is mediated by factors released by both FLS and synovial tissue macrophages and enhances the ingress of leukocytes into the synovial tissue, is insufficient, and the aggressive front formed by the hyperplastic synovial lining increases the distance between blood vessels and synoviocytes (32, 33) . RA FLS are transformed from a quiescent state to an aggressive, invasive phenotype, and they persist despite enrichment of apoptosisinducing factors such as oxygen radicals, nitric oxide, and cytokines supplied by activated synovial tissue macrophages. As such, the synovium bears resemblance to tumor tissue, and cells are likely to be subject to elevated bioenergetic and biosynthetic demands similar to those seen in cancer. This comparison is summarized in Figure 1 .
It is likely that adaptation of mitochondria and cytoplasmic metabolic pathways is needed to meet the requirements of chronic inflammation in RA. Indeed, in the few studies that profiled the metabolome of FLS, profound metabolic differences were identified in endstage RA compared with osteoarthritis, and many of these are described below (34, 35) . Our unpublished data showed a correlation between systemic inflammation (as measured by the CRP level) and the metabolic profile of FLS from patients with very early RA. However, there are few studies comparing FLS from patients with early RA with FLS from healthy subjects or assessing changes during the transformation to a chronically activated phenotype in early disease. Consequently, we are currently unable to determine whether metabolic adaptation of fibroblasts is a normal response to chronic inflammation or whether primary changes to cellular metabolism might themselves underlie or contribute to disease pathogenesis. There also are few studies of synovial tissue macrophages, and most of what is known about RA macrophage metabolism is based on animal models or studies of cells differentiated in vitro from SF or peripheral blood monocytes (36) . Because macrophages in healthy synovium are thought to be largely yolk sacderived, and cues leading to monocyte differentiation in tissue are poorly defined, there is a pressing need for better characterization of synovial macrophage subsets and their metabolism (37) .
The dynamic metabolic response in health
The function of the metabolic machinery within a cell is to provide the energy and biomolecules necessary to perform resting and activated functions while managing the production of potentially damaging by-products such as lactate and reactive oxygen species (ROS). Recent studies of immune cells have identified important roles for metabolism in supporting and even directing cell differentiation and fate. These studies have characterized the extent of metabolic plasticity required for cellular responses to stimulation (8) . Six main pathways are involved in these functions (see Figure 2 ). Of these, oxidative phosphorylation (comprising the tricarboxylic acid [TCA] cycle and the mitochondrial electron transport chain) and fatty acid oxidation are oxygen dependent and take place in the mitochondria while utilizing substrates taken up from the cytoplasm. Glycolysis, the pentose phosphate pathway, amino acid metabolism, and fatty acid synthesis are oxygen independent and largely take place in the cytoplasm. However, fatty acid and amino acid intermediates are also shared with mitochondrial processes, and use of the pentose phosphate pathway to maintain redox balance requires oxygen (8) .
Normal physiologic metabolism and metabolic responses to inflammatory events are poorly studied in tissue-resident populations such as fibroblasts and embryonically seeded macrophages (25) . This is largely due to the practicality of disentwining cells from the extracellular matrix, a challenge that researchers are making great efforts to address (38) . Indeed, there has been limited progress since the stromal cell metabolism field was thoroughly reviewed in 2014 (39) . One study defined what is known about resting healthy fibroblast metabolism, showing that foreskin-derived cells are predominantly glycolytic and dependent on the pentose phosphate pathway even during quiescence (40) . These pathways lead to biomolecule synthesis and support the anabolic processes associated with extracellular matrix production and this is likely to also apply to FLS, which maintain SF and produce it in excess in RA.
Reversible regulation in the balance of cytoplasmic and mitochondrial metabolism is crucial for all cells to respond and adapt to changing microenvironments. Metabolic change is orchestrated by signaling pathways responding to nutrient energy and oxygen levels as well as growth factor, pattern recognition, and cytokine receptors. The pathways involved have been reviewed previously (41, 42) and are summarized in Figure 2 . These include the master regulators mechanistic target of rapamycin (mTOR) pathway and 5 0 -adenosine monophosphate-activated protein kinase (AMPK) pathway, which work in opposition to one another. The mTOR network is a nutrient-sensing system.
Mechanistic target of rapamycin complex 1 (mTORC-1) or mTORC-2 complex formation downstream of the phosphatidylinositol 3-kinase (PI3K) pathway or the MAPK pathway induces activation of Akt and transcription factors hypoxia-inducible factor 1a (HIF-1a) and Myc, which in turn activate glycolytic pathway genes up-regulating aerobic glycolysis. Sterol regulatory element binding proteins and peroxisome proliferator-activated receptor c (PPARc) acting downstream of mTORC-1 also activate genes that up-regulate fatty acid synthesis.
Other pathways have also been shown to activate glycolysis in an HIF-1a-independent manner, including the NF-jB pathway involving ubiquitous phosphofructokinase 2. AMPK is an energy-sensing system that often is considered to be a metabolic checkpoint, because it can inhibit glycolysis, control cell proliferation, and promote mitochondrial biogenesis when activated under conditions of energetic stress (43, 44) . Downstream nuclear respiratory factor 1 (NRF-1), NRF-2, and PPARc coactivator 1a (PGC-1a), as well as sirtuin 1-or STAT-6-activated PGC1b, induce mitochondrial biogenesis and fusion (discussed below), induce protective antioxidant enzymes, and promote oxidative metabolism. The mTOR pathway has also been shown to be important in polarization of macrophages to proinflammatory (M1) or pro-resolving (M2) phenotypes and in activation of both macrophage subtypes, and this has Figure 2 . Major pathways important in synoviocyte metabolism. Fibroblast-like synoviocytes (FLS) and monocyte-derived macrophages are heavily reliant on glucose metabolism and regulate glucose transporter member 1 (GLUT-1) in response to inflammatory and stress stimuli. This fuels ATP production under conditions of high energy demand. Glucose is used in the pentose phosphate pathway to synthesize building blocks for nucleic acids and to generate NADPH to control redox status and support lipid synthesis. Alternatively, glucose is metabolized via glycolysis to pyruvate, which either is transported into the mitochondria to contribute to tricarboxylic acid (TCA) cycle flux or is converted to lactate in the cytoplasm and removed from the cell via monocarboxylate transporter 4 (MCT4). TCA cycle flux contributes to ATP production via oxidative and substrate-level phosphorylation. When matrix citrate levels rise, citrate is transported to the cytoplasm and yields acetyl-coenzyme A (acetyl-CoA), the starting material for synthesis of fatty acid (FA), cholesterol, and lipids. Some such lipids are exported from the cell as bioactive metabolites such as sphingosine 1 phosphate (S1P), free FA (FFA), phospholipids, and eicosanoids. Acetyl-CoA as well as succinate generated from the TCA cycle can be used in the production of chromatin-modifying enzymes (CMEs) and cofactors. Choline is taken up via choline transporter-like proteins 1 and 2 (CTL1/2) and is an important substrate in FLS biology. Choline can be converted to betaine, which is used in the production of CMEs and cofactors or converted to glycine for use in protein synthesis. Alternatively, choline is phosphorylated to phosphocholine and utilized in membrane phospholipid and bioactive lipid synthesis. A number of signaling molecules that control the described metabolic pathways have been identified but have been explored sparsely in FLS. mTOR = mechanistic target of rapamycin; AMPK = 5 0 -adenosine monophosphate-activated protein kinase; p53 = cellular tumor antigen p53; uPFK = ubiquitous phosphofructokinase 2; PI3K = phosphatidylinositol 3-kinase; P choline = phosphorylated choline; Myc = Myc proto-oncogene protein; HIF-1a = hypoxia-inducible factor 1a; G6P = glucose-6-phosphate; R5P = ribose-5-phosphate; SREBP = sterol regulatory element binding protein; PPARc = peroxisome proliferator-activated receptor c.
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FALCONER ET AL The enzymatic synthesis of molecules from smaller components. Anaplerosis
The replenishment of metabolic intermediates into the TCA cycle as substrates for biosynthesis and the generation of ATP. Bioenergetics
The study of energy production by cells. Often associated with use of a Seahorse analyzer to assess glycolysis and oxidative phosphorylation rates in real time.
Catabolism
The enzymatic degradation of molecules into smaller products. Cataplerosis
The removal of TCA cycle intermediates for use in biosynthesis or to prevent buildup within mitochondria. Electron transport chain A set of complexes of the inner mitochondrial membrane that shuttle electrons from NADH and FADH 2 to oxygen. The redox reactions of the chain produce an electrochemical gradient of protons across the membrane, which drives synthesis of ATP by oxidative phosphorylation. Hypoxia
Oxygen deficiency in tissue, such that oxygen tension is lower than that under healthy physiologic conditions. Normal oxygen levels differ between tissues, and therefore the level at which a tissue is considered to be hypoxic is variable. The arthritic joint has an oxygen tension of 8% in health and <3% in RA. Imaging mass spectrometry A mass spectrometry-based technique that allows the spatial distribution of the metabolome to be visualized in a tissue section. This offers insights into where pathogenic metabolic changes are taking place in tissues and
has not yet been applied to the synovium. Immunometabolism
The research field that investigates metabolism in the context of immunity and inflammation. Because stromal cells are crucial to both induction and resolution of these processes, we consider the study of their metabolic processes to be embedded in this field.
Metabolic coupling
The transfer of metabolites between cells in a manner that benefits the biosynthetic and bioenergetic requirements of the recipient cell. Metabolic flux analysis Also known as "stable isotope metabolic tracer analysis," this is a 13 C isotope-tracing methodology involving incubation of cells with a stable isotope, quantitation of metabolite labeling using mass spectrometry or NMR spectroscopy, and computational fitting of the data to a model, allowing estimates of pathway-specific flux.
Metabolic memory
Imprinting of a metabolic phenotype on a cell by cues within its microenvironment, such that the phenotype is maintained after the cues are removed or the cells are removed from the tissue. Metabolome All substrates, intermediates, and products of metabolism associated with a given system or compartment. These may be intracellular or extracellular. Metabolomics Used synonymously with the term "metabolic profiling," this is the identification and measurement of all or a targeted set of metabolites within a body fluid, cell population, or tissue, conducted by NMR spectroscopy or mass spectrometry.
Mitochondrial biogenesis
The generation of greater mitochondrial mass to increase the capacity for mitochondrial function and ATP production within a cell; this process is important to health but has not been investigated in RA.
Mitochondrial dynamics
The balance and transition between mitochondrial fusion and fission, movement, and degradation. These processes are important to health but have not been investigated in RA.
Mitochondrial fission
The division of mitochondrial networks into individual punctate organelles, principally controlled by outer membrane proteins DRP1 and FIS1.
Mitochondrial fusion
The formation of tubular mitochondrial networks through Mfn-1-, Mfn-2, and Opa-1-mediated joining of individual organelle membranes. This process is associated with increased ATP production and protection of mitochondrial DNA from reactive oxygen species. Mitophagy Mitochondrial-selective autophagy. The selective degradation of defective mitochondria without the release of inflammatory mitochondria-associated DAMPs. Oxidative phosphorylation Generation of ATP by mitochondrial ATP synthase and driven by the electrochemical gradient of protons generated by the electron transport chain. Pentose phosphate pathway
The pathway that oxidizes glucose to generate NADPH for the maintenance of the cellular redox balance and 5 carbon sugars utilized in anabolic processes such as nucleic acid synthesis. Positron emission tomography Use of a radioactive tracer isotope incorporated into a metabolic substrate to visualize metabolizing cells in a whole organism. Commonly, labeled glucose is used to identify tumors but also is useful for highlighting sites of inflammation such as the rheumatoid joint. Reverse Warburg effect
The production of high-energy metabolic intermediates by one cell to anaplerotically feed ATP production by a neighboring cell. This effect is currently characterized only in epithelial tumors where cancer-associated fibroblasts feed lactate and other metabolites to tumor cells through channels such as monocarboxylate transporters.
TCA
The TCA cycle is a series of chemical reactions that take place in the mitochondrial matrix, generating ATP by substrate-level phosphorylation and NADH and FADH 2 by oxidation of fuel molecules. NADH and FADH 2 are further oxidized by the electron transport chain. Warburg effect Pathologic increase in glycolysis associated with reduced oxidative phosphorylation despite the presence of oxygen. The term describes a cellular bioenergetic phenotype classically associated with tumor cells but currently also associated with activated immune cells.
* TCA = tricarboxylic acid; RA = rheumatoid arthritis; NMR = nuclear magnetic resonance; DRP1 = dynamin-related protein 1; FIS1 = mitochondrial fission 1; Mfn-1 = mitofusin 1; Opa-1= optic atrophy 1; DAMPs = damage-associated molecular patterns.
been thoroughly reviewed (45) . AMPK activation in macrophages is associated with suppression of IL-6 production, antiinflammatory M2 macrophage differentiation from SF monocytes, and suppressed inflammation in K/BxN mouse serum-induced arthritis (46, 47) . The signaling pathways that instruct stromal cell behavior are less well defined. Activation of mTOR has been linked to invasive properties in FLS from arthritic rats (48) . Furthermore, mice deficient in NRF-2, which acts downstream of AMPK, showed more severe cartilage injuries and more oxidative damage in a murine model of arthritis (49) . However, no link between metabolism and cell signaling has been identified in human FLS or synovial tissue macrophages, and it is unknown whether signaling pathways controlling the metabolic phenotype are dysregulated in RA.
Mitochondrial responses in the RA synovium
Under normoxic conditions, mitochondrial oxidative phosphorylation is the most efficient source of ATP (50) . In addition, mitochondria integrate various metabolic pathways and through this process produce intermediates needed for the synthesis of lipids, steroid hormones, and heme. Other more specialized mitochondrial functions include maintenance of Ca 2+ homeostasis, regulation of apoptosis, and production of the physiologic levels of ROS that act as signaling molecules (50) . Importantly, mitochondria have mechanisms to respond spatially and temporally to heterogeneous nutrient and oxygen concentrations, increased ATP demands, and increased stress signals, including oxidative stress, for continued support of cellular functions and survival. These mechanisms include overexpression of antioxidant enzymes and remodeling of respiratory complex subunits, changes in substrate usage (using glutamine, pyruvate, fatty acids, and ketone bodies), or switching toward increased glycolysis when energy demand outpaces oxygen delivery (50) .
Changes in mitochondrial biogenesis, mitochondrial-selective autophagy (mitophagy), and the equilibrium between mitochondrial fusion and fission are also critical to maintain normal mitochondrial and cellular function (Table 1 and Figure 3 ). Mitochondrial biogenesis is induced through the signaling pathways described above, not only in association with cell division but also in response to oxidative stimuli and increased energy requirements. The flux between fusion and fission of mitochondria in response to stress is also crucial to maintaining the metabolic capacity of the mitochondria as well as protecting genetic stability. Mitophagy plays a pivotal role in the maintenance of mitochondrial homeostasis, by regulating the size and quality of the mitochondrial population. In addition, mitophagy eliminates damaged mitochondria under diverse stress conditions, which is critical because mitochondrial DNA (mtDNA) is a damage-associated molecular pattern molecule that contributes to systemic inflammatory responses (51) . Modulation of mitochondrial dynamics, biogenesis, and mitophagy can be deleterious and associated with aging in mouse models and multiple serious human diseases, highlighting the importance of these processes in cell phenotype and function (51, 52) . Furthermore, mitochondrial surveillance and quality control mechanisms including mitochondrial biogenesis and mitophagy decline with age, causing progressive deterioration of mitochondrial function. This may have a role in diseases such as RA and suggests that targeting mitochondrial processes could be beneficial for restoring cell function (53) .
Surprisingly little is known about mitochondrial function and dynamics in FLS or synovial tissue macrophages. However, a growing body of literature describes mitochondrial metabolism downstream of glycolytic glucose consumption and its role in differentiation and activation of proinflammatory and pro-resolving monocytederived macrophage subtypes. These model systems might inform synovial tissue research. For example, stimulation of macrophages with lipopolysaccharide and IFNc (so-called M1-polarizing conditions) produces proinflammatory cells that may resemble those that populate the RA synovium. This leads to inhibition of the TCA cycle and the mitochondrial oxidative phosphorylation pathway to which it is coupled, and results in up-regulation of glucose transporter 1 (GLUT-1) to facilitate efficient uptake of glucose.
Glucose is consumed through up-regulated aerobic glycolysis, resulting in production of lactate, which must be extruded from the cell to prevent damaging lactic acidosis (54) . Production of reactive oxygen is increased, partly as a consequence of reversed electron transport by mitochondria, and certain intermediates of the TCA cycle (notably, succinate) accumulate. This promotes expression of the proinflammatory cytokine IL-1b by inhibiting prolyl hydroxylases and activating the transcription factor HIF-1a. Succinate has also been linked to changes in methylation of DNA and associated histone proteins to alter gene expression (55) . Furthermore, isocitrate is diverted from the Krebs cycle and metabolized to itaconic acid, which is another, more recently identified TCA cycle inhibitor (56) . RA synovial macrophages express HIF-1a, consistent with a switch to glycolytic metabolism, but efforts are required to characterize mitochondrial metabolism and dynamics in resident and infiltrating synovial tissue macrophages (57) .
In several studies, mitochondria were observed in FLS from patients with late-stage RA. Reductions in 990 FALCONER ET AL respiration and membrane potential (58) and changes to mitochondrial morphology (50) have been observed in unstimulated cells when compared with OA FLS. Further changes suggestive of mitochondrial dysfunction such as perinuclear clustering of mitochondria, abnormally dark cristae, and autophagosome formation have been associated with lower basal mitochondrial membrane potential as well as lower basal, maximum, and ATP-linked mitochondrial respiratory rates (58) . In a complementary study in which RA FLS were compared with OA FLS, our group recently showed that RA FLS had a higher ratio of glycolytic rate to respiratory rate, implying a shift toward reliance on glycolysis to meet the energy demand of the cells (60) . Changes in mitochondrial metabolism can be induced in FLS by cytokines and growth factors, including IL-17, TNF, and platelet-derived growth factor (PDGF), which are associated with RA and related inflammatory conditions (58, 61) . The reported consequences, although incompletely understood, include Figure 3 . Mitochondrial fusion and fission cycle. Mitochondrial morphology changes dynamically in response to stress and changing energy demand. This occurs under the control of signaling molecules including sirtuin 1 (SIRT-1), STAT-6, nuclear respiratory factors 1 and 2 (Nrf-1/2), and peroxisome proliferator-activated receptor c (PPARc) coactivators 1a and b (PGC-1a/b). Mitochondria fuse to make tubular networks under the control of mitofusins 1 and 2 (Mfn-1) and optic atrophy 1 (Opa-1), a mechanism that is thought to increase ATP production by oxidative phosphorylation, protect mitochondrial DNA (mtDNA) from damage in the presence of elevated levels of reactive oxygen species (ROS), and lead to mitochondrial biogenesis and increased mitochondrial mass. Mitochondrial fission occurs under the control of dynamin-related protein 1 (DRP1) and mitochondrial fission 1 (FIS1) and produces increased numbers of punctate mitochondria. Fission usually corresponds with reduced oxidative phosphorylation and increased aerobic glycolysis and can predispose to mitochondrial-selective autophagy (mitophagy) to regulate mitochondrial mass or remove damaged organelles. Inset, Mitochondrial changes in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS), in a resting state and after stimulation with proinflammatory cytokines, suggesting possible changes in mitochondrial dynamics that have not yet been investigated. NO = nitric oxide.
reduced ATP production by oxidative phosphorylation, production of excessive reactive oxygen and nitrogen species, dysregulation of Ca 2+ , opening of the permeability transition pore, and initiation of cell death in vitro.
Significant increases in mtDNA mutation frequency have been demonstrated in inflamed synovial tissue and were positively correlated with macroscopic synovitis, vascularity, and SF levels of TNF and IFNc (62) . Another study showed that exposure of RA synovial tissue to 1% oxygen in vivo induced mtDNA mutations, suggesting that the inflamed and hypoxic joint microenvironment may be eliciting the mitochondrial changes observed in RA FLS and likely to be occurring in synovial tissue macrophages (31) . Hypoxia also altered the bioenergetics of cultured FLS by promoting a switch to glycolysis while attenuating mitochondrial respiration and ATP synthesis. This supported abnormal angiogenesis, cellular invasion, and pannus formation (59) . Additional in vitro studies indicated an increased number of mtDNA mutations and ROS levels in RA FLS compared with OA FLS (63), correlating with elevated matrix metalloproteinase expression and an invasive phenotype in RA (61, 64) .
The findings described above suggest that there are mitochondrial changes in FLS from patients with latestage RA that are maintained in in vitro culture, yet we lack understanding regarding which changes are a normal response to meet metabolic demands of inflammation, which might play a role in driving the pathology of chronic disease and which are the result of damage and an increasingly hypoxic environment. In fact, resistance to induction of programmed cell death (apoptosis) by apoptotic signals abundant in the inflamed joint is a prominent characteristic of the RA synovium (65) and sustains the synovial hyperplasia that characterizes the rheumatoid pannus. This would suggest that mitochondrial responses induced by hypoxia and inflammation in synoviocytes are able to repurpose the mitochondrion as a biosynthetic hub similar to that in tumor cells (66) and with conserved mechanisms for limiting oxidative stress and supporting effector functions and proliferation (5) . Finally, although information regarding mitophagy in the synovium is lacking, it has been suggested that TNF significantly induces mitophagy and mitochondrial antigen presentation in mouse macrophages, with implications for RA (67) .
Several studies have shown altered autophagy in RA FLS, which could also contribute to synovial hyperplasia. RA FLS show an increase in genes involved in autophagy such as beclin 1 and light chain 3, which are inversely correlated with their apoptosis rate (68, 69) . In addition, RA FLS under endoplasmic reticulum stress may increase autophagy while becoming resistant to apoptotic death (70) . Further studies are needed to understand the tangled relationship between metabolism, apoptosis, and autophagy in synoviocytes and to identify whether restoring normal metabolism and mitochondrial function might have therapeutic potential in RA.
Glucose metabolism in the RA synovium
Glucose and other metabolites such as glutamine, fatty acids, and ketone bodies can be metabolized through the TCA cycle in metabolically active tissue, but a shift away from oxidative phosphorylation toward aerobic glycolysis often occurs in response to cellular activation and in inflamed tissues (71) . This supports various biosynthetic pathways and, consequently, the metabolic requirements for proliferation and cytokine production. Accelerated glucose metabolism is a hallmark of proliferative and activated cells (72) and can be observed with clinical imaging. Several studies have used fluoro-2-deoxyglucose (FDG), which is taken up by glycolytic cells to form FDG phosphate and can be shown by positron emission tomography (PET) to accumulate in swollen joints (73) . Indeed, glycolytic inhibition by 3-bromopyruvate (BrPa) administered in a serum transfer animal model significantly decreased arthritis severity, highlighting the importance of glucose metabolism in fueling pathologic processes and making it a promising target for therapeutic intervention in RA (60) . However, as discussed in a recent review by Weyand and Goronzy comparing macrophages and T cells, cells can coexist in the same microenvironment and utilize metabolites differently (74) . This highlights the need to dissect glucose utilization in different synoviocytes, because any successful treatment will necessarily be cell type specific.
Metabolic profiling of synovial tissue has revealed that FLS consistently show altered basal glucose metabolism in RA (34, 35, 75) , and we and other investigators have observed that stimuli such as PDGF and TNF increase in vitro glucose metabolism by both glycolysis and mitochondrial respiration (60) . Furthermore, the glucose channel GLUT-1 is up-regulated in response to hypoxia and cytokines and is correlated with phenotypic perturbations in RA FLS (59, 60) . Glucose deprivation or glycolytic inhibitors such as 2-deoxy-D-glucose, BrPa (60) , and 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (59) have been shown to impair cytokine secretion, proliferation, migration, and invasion in RA FLS. Although glucose metabolism is enhanced in activated macrophages, no data for synovial tissue macrophages are currently available.
Diversion of glucose metabolism away from glycolysis and toward the pentose phosphate pathway is important to support a biosynthetic role of some cells. A role for this pathway in RA was highlighted by a study of T cells, which showed impaired glycolytic flux due to elevated pentose shunt activity and up-regulation of phosphofructokinase (76) . In light of RA synoviocyte mitochondrial responses and the elevated ROS production described above, increased flux of glucose through the pentose phosphate pathway might also be expected in these cells to produce cytoplasmic NADPH and drive the reducing power of ROS detoxification enzyme systems in both the cytoplasm and the mitochondrial compartments. Indeed, a global increase in glucose metabolism (via both the pentose phosphate pathway and glycolysis) was observed in total synoviocytes (4), and recent metabolite profiling of FLS (77) showed that both metabolites associated with glycolysis and the pentose phosphate pathway were significantly increased in RA compared with OA, together with other metabolites that belonged to the amine, fatty acid, phosphate, and organic acid classes. Although this hints at the importance of the pentose phosphate pathway, its role, and the importance of NADPH production and other antioxidant mechanisms such as the up-regulation of the glutathione oxidation pathway have not yet been dissected in FLS and resident synovial tissue macrophages populations, and such research might yield new opportunities for therapeutic intervention in RA.
Functions have emerged for glucose metabolites, metabolic enzymes, and TCA cycle intermediates, which are secondary to their canonical roles in metabolic pathways. For instance, succinate stabilizes the transcription factor HIF-1a in activated macrophages and also rat synovial fibroblasts, promoting glycolysis (55, 78) . Succinate and other metabolites including a-ketoglutarate, fumarate, and acetyl-coenzyme A might be expected to accumulate in macrophages and FLS under hypoxic conditions and are involved in eliciting important epigenetic changes, with the potential for driving chronic inflammation remaining unexplored (55, 78) . In addition, essential glycolytic enzymes have been reported to translocate to the nucleus or mitochondria, where they function independently of their canonical metabolic roles in the regulation of cytokines and antiapoptotic responses (79, 80) . For example, pyruvate kinase muscle enzyme M2 (PKM2) also stabilizes HIF-1a, promoting inflammatory M1-type macrophage differentiation. Use of a small-molecule modulator of PKM2 to prevent nuclear translocation has potential for driving a shift toward an M2 phenotype and restoration of tolerance in diseases such as RA.
The hexokinase enzymes are also important regulators of metabolism. Hexokinase type I is known to drive cleavage and activation of pro-IL-1b in macrophages via the NLRP3 inflammasome and the downstream activation of caspase 1 (81) , although this has not been studied in synovial tissue macrophages.
Hexokinase type II also binds to the mitochondrial membrane via its interaction with the outer membrane porin protein (also termed the voltage-dependent anion channel), and this interaction inhibits the release of intermembrane proapoptotic proteins, thereby protecting cells against apoptosis. Importantly, the expression of hexokinase type II is increased in RA FLS compared with OA FLS, and this might provide an important link between metabolism and apoptosis resistance in the RA synovium (60) .
Lipid metabolism in the RA synovium
Lipids are known to be important for fueling adaptive immunity and in the resolution of inflammation. However, their role in these processes is complex and our understanding incomplete (8, 82) . A few studies have shown lipid changes in RA FLS, although this has not been studied in synovial tissue macrophages. Metabolomic profiling has shown a perturbation of lipid metabolism in RA FLS versus OA FLS (34) , and recent studies have identified important roles for molecules that interact with lipids such as choline, an important component of membrane phospholipids that may be limiting in proliferating cells such as RA FLS. PET scanning with 11 C-choline, which is already in clinical use to identify prostate cancer metastasis, showed increased uptake in inflamed arthritic joints (83) , and choline is present at elevated levels in RA FLS and synovium (34, 75) . It is of interest that choline transporter-like protein 1 (CTL1) (high affinity) and CTL2 (low affinity) are also highly expressed in RA FLS, and the functional inhibition of choline transporters promoted apoptotic FLS death (84) .
Our group previously reported a possible therapeutic benefit in targeting choline kinase, the enzyme that catalyzes the first step in the cytidine diphosphate/choline pathway and that is essential for phosphatidylcholine biosynthesis. Inhibition of choline kinase suppressed migration and enhanced apoptosis in cultured RA FLS and significantly "decreased arthritis in pretreatment protocols as well as in established disease" (35) . In addition, phospholipase enzymes specifically cleave phosphatidylcholine, producing phosphatidic acid and choline. Agonist-induced phospholipase D activation results in phosphatidic acid synthesis, which is thought to be involved in a variety of rapid cellular responses such as cytokine secretion (85) . In RA FLS and RA synovial biopsy explants, phospholipase D isoform-specific inhibitors significantly reduced constitutive secretion of IL-6 and IL-8, further highlighting the importance of phospholipid metabolism in inflammation (86) . Another study showed that activated FLS from patients with inflammatory arthritis and animal models of inflammatory arthritis express significant quantities of autotaxin, which catalyzes the conversion of lysophosphatidylcholines (LPCs) to lysophosphatidic acid (LPA). Notably, high levels of LPC and low phosphatidylcholine: LPC ratios in plasma were shown to represent a reliable measure of inflammation (87) . TNF-induced autotaxin expression in FLS and LPA, in turn, induced an activated FLS phenotype in synergy with TNF (88, 89) . Conditional genetic ablation of autoxin in mesenchymal cells, including FLS, resulted in disease attenuation in animal models of arthritis (90) .
Metabolic coupling of cells in the RA synovium
The problem with many of the studies described above is that they tend to treat FLS and synovial tissue macrophages as if they exist in isolation. However, metabolism is not a private function, and metabolites produced by one cell can have profound effects on the biology of another. As described above, metabolites such as succinate, citrate, and isocitrate accumulate in inflammatory macrophages and control metabolism in a feedback loop. It is possible that such metabolites derived from synovial tissue macrophages might have a role in influencing the metabolism and function of proximal FLS, but this has not yet been investigated. Indeed, metabolite exchange between stromal and parenchymal cells is an essential function common to numerous metabolically active tissues including muscle, nerve, kidney, liver, and testicle.
Solute carriers including the monocarboxylate transporters (MCTs) are used as a means of physiologic metabolic coupling between different cell types, as extensively reviewed (91) . Here, macrophage-like cells Figure 4 . The reverse Warburg effect in cancer and rheumatoid arthritis (RA). In epithelial tumors, the reactive oxygen species (ROS) produced by metabolically active cancer cells cause mitochondria-selective autophagy (mitophagy) and activate HIF-1a in local cancer-associated fibroblasts (CAFs). As a result, the CAFs up-regulate aerobic glycolysis, producing copious lactate that is expelled from the cell via MCT4 and taken up by the cancer cell via MCT1. Lactate, pyruvate, and other metabolic intermediates such as amino acids and ketone bodies can feed the mitochondrial TCA cycle in cancer cells or local endothelium to increase ATP and biomolecule synthesis and drive pathogenic proliferation, invasion, and metastasis. MCT1 and MCT4 can be blocked in vitro using the small-molecule inhibitor a-cyano-4-hydroxycinnamic acid (4CIN) and in vivo using AZD3965, which is in early-phase clinical trials for treatment of small cell lung cancer. In RA, it is known that mitochondrial damage, HIF-1a activation, and up-regulation of MCT4 can be induced by the pathogenic microenvironment in fibroblast-like synoviocytes (FLS) from patients with late-stage disease, but the metabolic relationships between these cells and other cells within the joint have yet to be elucidated. See Figure 2 for other definitions.
commonly provide high-energy metabolic intermediates such as lactate and pyruvate to bioenergetically demanding partner cells, where they can anaplerotically fuel the TCA cycle. A similar mechanism has been identified in epithelial cancers in which both Warburg and so-called "reverse Warburg" metabolism have been demonstrated and highlighted as therapeutic targets (92) . The Warburg effect describes up-regulation of aerobic glycolysis in the tumor cell itself and in the presence of ample oxygen.
The reverse Warburg effect describes a situation in which cancer-associated fibroblasts provide lactate, ketone bodies, and amino acids passed through MCTs to fuel tumor cell proliferative behavior (93) , as well as local angiogenesis associated with metastasis (94) . Due to commonalities in cell behavior and microenvironment, one could hypothesize that similar symbiotic relationships might exist in the synovium to fuel immune cell effector function and FLS pathogenic behavior (Figure 4 ). Fujii et al previously showed that FLS from patients with latestage RA have elevated levels of MCT4 compared with OA FLS, and that small interfering RNA knockdown of MCT4 reduced arthritis severity in the murine collageninduced arthritis model, linking their findings to apoptosis resistance and synovial acidification (95) .
Expulsion via MCT4 is likely to be a necessary mechanism to protect cells against the damaging effects of lactate accumulation. However, whether the lactate can be taken up and utilized by other cells is unknown. It is very likely that the role of MCTs and the sharing of metabolites between cells will differ during the course of RA as a reflection of mitochondrial health and changes to the joint microenvironment. Consequently, it will be important to study metabolic coupling in normal tissue and during the acute phase of disease to determine whether such relationships exist and if so, to exploit their therapeutic potential; such an approach is showing promise in cancer (96) .
Expanding knowledge of fibroblast metabolism
Studies of metabolism in cultured synovial cells have been important for understanding RA biology. Such studies have illustrated a "metabolic memory" that is epigenetically imprinted upon cells in an inflammatory microenvironment and is lasting in in vitro culture. Metabolomic analysis continues to be a useful strategy for providing a metabolic snapshot of the status of such cells and to hint toward pathways worthy of further study. Use of technologies such as Seahorse analysis to observe bioenergetic responses, small-molecule metabolic inhibitors, and animal models have also played a role in expanding our understanding of the field. However, for capturing the dynamic processes that regulate cellular metabolism, stable isotope metabolic tracer analysis is a powerful technique that has not yet been applied to synoviocytes (97) . This technique provides a comprehensive biologic overview, allowing simulation and reconstruction of metabolism, and can provide insight at the compartment level (e.g., mitochondria versus cytoplasm, depending on the tracer) (98) . The increased concentration of a metabolite can be associated with either the up-regulation of the enzyme responsible for synthesis or the down-regulation of the one consuming it, and metabolic tracer analysis allows these processes to be deconvoluted where traditional metabolomics is less informative (99, 100) . Several heavy isotopes are available and include 2 H, 15 N, and 18 O, but the most commonly used is 13 C. The most common isotopically labeled tracers are 13 C-labeled glucose and 13 C-labeled glutamine, because these metabolites are the main energy sources in many mammalian systems (101) . The recent development of approaches to apply tandem mass spectrometry (MS) to isotope tracing has offered the opportunity to determine positional labeling based on mass fragmentation (102) .
As alluded to above, studying metabolic relationships of synoviocytes after treatment (103) and between FLS and synovial tissue macrophages within the RA synovium is an important future direction. Stable isotope analysis in concert with small-molecule inhibitors will allow us to trace metabolite exchange between cells in culture. There is also a pressing need for conditional knockout animals to observe the importance of metabolite channels, transporters, and enzymes in inflammatory diseases as an area of great therapeutic potential. Finally, better histologic markers are improving our understanding of FLS subsets, resident and infiltrating synovial tissue macrophages, and the tissue organization of these cells. Imaging MS can provide a metabolomic snapshot on a per-pixel basis and may reveal spatially distinct metabolic signatures and important metabolic heterogeneity within the synovial environment (104) .
Metabolic pathways as therapeutic targets in RA
Metabolic rewiring of immune cells has been viewed as a promising source of novel drug targets (8, 14, 105) , but resetting metabolism in tissues central to RA pathogenesis offers additional opportunities for disease modulation and restoration of homeostasis in RA. In fact, rheumatologists already use the antimetabolites methotrexate and leflunomide for the treatment of patients with inflammatory arthritis. Both drugs inhibit reproduction of rapidly dividing cells such as lymphocytes but have also been shown to inhibit FLS functions (106, 107) . Of interest is the observation that sulfasalazine, which was initially developed as an antiinflammatory drug to treat RA, was subsequently shown to inhibit xCT, a cystine-glutamate exchange transporter (108) .
Targeted approaches to metabolic inhibition are required to inhibit aggressive behavior in pathologic cell types and leave those that aid resolution intact. Potentiation or restoration of protective mechanisms such as mitochondrial fusion and biogenesis and mechanisms that promote resolution of inflammation may also be favorable. Indeed, small molecules such as Mdivi-1 that potentiate mitochondrial fusion have already shown potential in animal models of sepsis and may have further-reaching applications (109) . In addition, metformin is used for the clinical management of type II diabetes and has shown promise in mouse models of arthritis (110) . Although the effects of metformin on FLS are unknown, it is thought to act on immune cells both by inhibiting complex I of the mitochondrial electron transport chain and through effects on the signaling molecule AMPK. Use of other AMPK activators that will control cell proliferation and promote mitochondrial biogenesis might be another approach (43, 44) .
The signaling molecule PI3K regulates glycolysis upstream of mTOR, and inhibitors of this molecule are in early-stage clinical trials for cancer and show potential in RA (111) . Furthermore, blockers of key glycolytic enzymes including phosphofructokinase/fructose-2,6-bisphosphatase 3 are showing promise for working in synergy with other inhibitors that target the angiogenic factor vascular endothelial growth factor (112) . Inhibiting glycolytic intermediates including succinate or lactate production could be of interest if proven to fuel synovial cell activation. Use of a small-molecule modulator of PKM2 to prevent nuclear translocation also has potential for driving a shift toward an M2 phenotype and restoration of tolerance in diseases such as RA. In FLS, HK2 release from the mitochondrial membrane could potentially trigger FLS apoptosis. However, a better understanding of the signaling pathways that dictate the metabolic phenotype of immune and stromal cells in RA is required to capitalize on this area.
Blockers of the MCTs that are central to metabolic coupling have been used in as yet unpublished first-inman trials for epithelial cancers, and the effects of their knockdown in experimental arthritis suggest that they offer potential in RA (95) . Other solute carrier transporters, including GLUT-1, amino acids, or choline, are potential therapeutic targets that are yet to be explored in arthritis. Furthermore, better stratification of patients through prognostic metabolomic analysis (16) and techniques such as PET scanning with 11 C-choline (83) may improve treatment of patients who are nonresponders to existing therapies. Overall, whether targeting metabolism truly presents an option to increase the drug armamentarium in rheumatic diseases remains to be determined.
Conclusions
Systemic metabolism, immunometabolism, and stromal cell metabolism are altered in RA, and a growing body of literature in this field offer novel biomarkers for patient stratification and avenues for treatment. However, we are far from having an exhaustive understanding of the pathways that discern the normal or pathogenic phenotypes of synovium-resident cells in order to capitalize on these therapeutic opportunities. It will be important to better understand mitochondrial metabolism and dynamics, which are sparsely studied in the synovium, with a view to harnessing fusion and biogenesis pathways to restore mitochondrial health and tip the balance away from aerobic glycolysis in RA. Future directions toward use of cells sorted directly from synovial tissue and phenotyping with single-cell transcriptomic analysis promise to improve our understanding of FLS and synovial tissue macrophage biology, and there is a need for metabolic profiling of these cells prior to de-differentiation associated with cell culture.
Growing evidence suggests that multiple fibroblast and macrophage subsets are present in the inflamed synovium, and their characterization will aid in directing new treatment aimed at those with a pathogenic and not a protective phenotype. Furthermore, the metabolic interactions between FLS, synovial tissue macrophages, and infiltrating immune cells have not been explored, and lessons from cancer biology suggest that this will provide further opportunities for therapeutic intervention. There is a pressing need for techniques such as stable isotope-based metabolic tracer analysis to track these interactions. Finally, there is a strategic window of opportunity such that RA patients receiving disease-modifying treatments within 3 months of symptom development show a much improved prognosis when compared with patients treated after this time point (113) . To date, all studies of FLS metabolism have been conducted in cells derived from the joints of patients with late-stage disease after arthroplasty, and studies of macrophages have used cells differentiated from monocytes in vitro.
As we begin to understand that transient metabolic responses in acute inflammation may differ significantly from metabolic adaptation to damage in chronic inflammation, characterization of cells from healthy tissue and from the earliest stages of human disease is needed to inform appropriate future therapeutic strategies, with the ultimate goal of drug-free remission or cure of RA. 996 FALCONER ET AL
